Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies

Vanda Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Allergic Conjunctivitis

Treatments: Drug: VSJ-110; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT04622345

VP-VSJ-110-2101

Details and patient eligibility

About

The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of allergic conjunctivitis using an antigen challenge model

Enrollment: 47 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• At least 18 years of age of either gender and any race
• Able to provide written informed consent and sign the HIPAA form
• Willing and able to follow all instructions and attend all study visits

Exclusion criteria

• Able and willing to avoid all disallowed medications during washout and study period

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

47 participants in 2 patient groups, including a placebo group

VSJ-110 Solution

Experimental group

Treatment:

Drug: VSJ-110

Placebo Solution

Placebo Comparator group

Treatment:

Drug: Placebo